The study will evaluate most commonly used
medical strains and the ailments they are best suited to
treat
TORONTO, Mar. 2, 2016 /CNW/ - Mettrum Health Corp.
("Mettrum" or the "Company") (TSXV:MT), a vertically
integrated licensed producer (LP) of cannabis products, this week
launched the Mettrum Registry Research Program (MRRP) to
systematically gather data on up to six thousand Canadian patients
who have been prescribed medical cannabis.
The goal of this observational study is to provide information
to prescribing physicians and the wider medical community to help
determine if and how cannabis should be prescribed – focusing on
which strains best suit a particular patient's needs. It also
considers the impact of intercurrent illness or potential
interactions with other medications. The study will run for one
year, with results anticipated to be published by March
2017.
"Our motivation for conducting this research is to ensure that
individuals who are prescribed Mettrum Dried Cannabis or Cannabis
oils, are able to receive the full potential of their
prescription," said Michael Haines,
CEO of Mettrum. "We believe the data gathered will generate a
greater understanding of the factors that influence how medical
cannabis is and should be prescribed. This includes which medical
strains are most commonly used and the medical conditions and
symptoms they most effectively address. We also hope to determine
how the effects of medical cannabis might be modified by other
conditions an individual has, or by other medications they might be
taking concurrently."
Through this research, Mettrum will be collecting information
relating to target conditions and/or symptoms, the presence of
other diseases, patient demographics and other medications that
these patients are actively taking along with the strain or strains
the patient is using to treat the medical condition and symptoms.
In addition, Mettrum will collect feedback from physicians on the
effectiveness of the cannabis treatment.
Beginning in March, physicians will opt-in to the MRRP online,
via the Mettrum Cannabis Electronic Medical Records (CEMR)
application. The CEMR allows for the creation and secure electronic
transmission of prescriptions and related patient registration
documents, as well as physician-only access to resource materials,
literature and the data from the study. The CEMR is also the data
collection platform for the MRRP.
The MRRP has been submitted and approved by the Canadian SHIELD
Ethics Review Board (www.cserb.com), and all patient and
prescribing physician information is protected. Any communication
or publications arising from this research will be described in
aggregate form, safeguarding the identity of the study
participants.
Mettrum is currently recruiting physicians interested in
becoming study investigators in this exciting and important
initiative. If you would like to learn more about the Mettrum
Registry Research Program, please contact Mettrum at 1-866-920-2009
or send an email to research@mettrum.com.
About Mettrum Health Corp
Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX
Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is a
Toronto-based company and licensed
producer of medical cannabis under the Marihuana for
Medical Purposes Regulations (Canada) (MMPR) issued pursuant to
the Controlled Drugs and Substances
Act (Canada). The
Company is a leading producer and vendor of medical cannabis under
the MMPR system and has three licensed production facilities
totalling 85,000 square feet representing annual production
capacity of approximately 12,000 kilograms.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements"
under applicable Canadian securities legislation. Forward-looking
statements are necessarily based upon a number of estimates and
assumptions that, while considered reasonable, are subject to known
and unknown risks, uncertainties, and other factors which may cause
the actual results and future events to differ materially from
those expressed or implied by such forward-looking statements. Such
factors include, but are not limited to: general business,
economic, competitive, political and social uncertainties; delay or
failure to receive board, shareholder or regulatory approvals; and
the results of operations. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements. The Company and Mettrum disclaim any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Neither the Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the Exchange) accepts
responsibility for the adequacy or accuracy of this Press
release.
SOURCE Mettrum Health Corp.